Even when statistically significant, increases in serum potassium are deemed “clinically modest,” and generally, the benefits of MR blockade are deemed greater than the risk of clinically relevant hyperkalaemia (Pisoni et al., 2012; Pitt et al., 1999, 2003). The gene discussed is NR3C2; the disease is Hyperkalemia.